Who are HAVpur Junior's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SARS-CoV-2 Inactivated Vaccine, EV71 inactived vaccine（Vero cells）, Sabin IPV + Sabin IPV + Sabin IPV, Havrix+Healive, HepA-I, fIPV (0.1mL) IM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/havpur-junior.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

HAVpur Junior — Competitive Intelligence Brief

HAVpur Junior (HAVpur Junior) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Hepatitis A virus (HAV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

HAVpur Junior (HAVpur Junior) — Crucell Holland BV. HAVpur Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HAVpur Junior TARGET	HAVpur Junior	Crucell Holland BV	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
SARS-CoV-2 Inactivated Vaccine	SARS-CoV-2 Inactivated Vaccine	PT Bio Farma	marketed	Inactivated viral vaccine
EV71 inactived vaccine（Vero cells）	EV71 inactived vaccine（Vero cells）	Sinovac Biotech Co., Ltd	marketed	inactivated viral vaccine	Enterovirus 71 (EV71) viral antigens
Sabin IPV + Sabin IPV + Sabin IPV	Sabin IPV + Sabin IPV + Sabin IPV	Zhejiang Provincial Center for Disease Control and Prevention	marketed	inactivated viral vaccine	poliovirus serotypes 1, 2, and 3
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
HepA-I	HepA-I	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
fIPV (0.1mL) IM	fIPV (0.1mL) IM	Centers for Disease Control and Prevention	marketed	inactivated viral vaccine	poliovirus serotypes 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HAVpur Junior — Competitive Intelligence Brief. https://druglandscape.com/ci/havpur-junior. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab